Overview

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

Status:
Terminated
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca